真实世界评估[177Lu]Lu-PSMA-617 RLT用于多西他赛治疗后mCRPC:个体化治疗的可行性与安全性
本研究基于前瞻性登记研究REALITY(NCT04833517)回顾性分析227例多西他赛治疗后、PSMA高表达的mCRPC患者,按体表面积归一化并依据肾功能、造血功能及肿瘤负荷调整每周期[177Lu]Lu-PSMA-617活度。中位随访15.9个月,中位PSA-PFS为5.1个月,中位OS为14.5个月,≥CTCAE 3级新发或加重的血液学或肾脏损害不常见。
要点
- 个体化剂量调整的[177Lu]Lu-PSMA-617 RLT在多西他赛治疗后mCRPC中可行且安全性可接受。
- 中位PSA-PFS为5.1个月,中位OS为14.5个月,51.5%患者PSA下降≥50%。
- 内脏转移和ALP≥220 U/L与PSA-PFS缩短相关。
核心结论
- 回顾性真实世界分析提示,个体化、剂量适配的[177Lu]Lu-PSMA-617 RLT可能在不影响安全性和生存结局的前提下,将RLT适用人群扩展至更具挑战性的临床场景和更广泛的患者群体。
研究设计与样本
- 前瞻性登记研究REALITY(NCT04833517)纳入227例多西他赛治疗后、PET/CT显示PSMA高表达的mCRPC患者,并进行回顾性分析。
- 每周期[177Lu]Lu-PSMA-617活度按体表面积归一化,并根据肾功能、造血功能、肿瘤负荷及进展参数进行调整。
- 采用Kaplan-Meier分析PSA-PFS和OS,采用Cox比例风险模型(后退法)识别结局预测因素,安全性按CTCAE v5.0评估。
主要发现
- 中位每周期给药活度为7.1 GBq(范围2.7-11.6 GBq),中位累积活度为22.3 GBq(范围2.7-77.8 GBq),患者中位接受3个周期,间隔6周。
- 中位随访15.9个月(95%CI:11.2-20.5个月)后,中位PSA-PFS为5.1个月(95%CI:4.0-6.2个月),中位OS为14.5个月(95%CI:11.4-17.7个月)。
- 63.9%的患者在第一周期后PSA下降,51.5%的患者PSA下降≥50%。
- PSA-PFS缩短与内脏转移(p=0.001)和ALP≥220 U/L(p=0.004)相关。
- OS缩短与内脏转移(p=0.009)、ALP≥220 U/L(p=0.001)、年龄≤65岁(p=0.034)、血红蛋白<9 g/dL(p=0.006)及1-2疗程后早期生化进展(p<0.001)相关。
临床怎么用
- 对于多西他赛治疗后、PSMA高表达的mCRPC患者,可考虑个体化剂量调整的[177Lu]Lu-PSMA-617 RLT。
- 治疗前应评估内脏转移、ALP、血红蛋白、年龄等基线因素,以识别可能获益有限的患者。
- 治疗早期(1-2周期后)出现生化进展可能提示OS缩短,需密切监测。
局限性
- 本研究为回顾性分析,可能存在选择偏倚和混杂因素。
- 个体化剂量调整方案与对照非个体化方案比较的结果未在摘要中详细报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Evaluating efficacy and safety of individualized [177Lu]Lu‑PSMA‑617 radioligand therapy in heavily pretreated post-taxane patients with metastatic castration‑resistant prostate cancer (mCRPC), and to present a comparison with outcomes of non-individualized regimens. METHODS: Per‑cycle activities of [177Lu]Lu-PSMA-617 were individualized by normalizing to body surface area and adjusting for renal clearance, hematopoietic function, and tumor burden and progression parameters. 227 post-taxane mCRPC patients with intense PSMA expression on PET/CT were enrolled in the prospective registry (REALITY; NCT04833517) and retrospectively analyzed. PSA progression-free survival (PSA-PFS) and overall survival (OS) according to Kaplan-Meier analysis, Cox proportional‑hazards models with backward elimination for identification of outcome predictors, safety assessment according to CTCAE v5.0. RESULTS: Median administered activity was 7.1 GBq per cycle (range 2.7-11.6 GBq) and cumulative activity 22.3 GBq (range 2.7-77.8 GBq), while patients received a median of 3 cycles within a 6-week interval. After a median follow‑up of 15.9 months (95%CI: 11.2-20.5 months), median PSA‑PFS was 5.1 months (95% CI: 4.0-6.2 months), and median OS 14.5 months (95% CI: 11.4-17.7 months). PSA declined after the first cycle in 63.9% of patients; PSA reduction ≥ 50% occurred in 51.5%. Shortened PSA‑PFS was associated with visceral metastasis (p = 0.001) and ALP ≥ 220 U/L (p = 0.004). Shortened OS was associated with visceral metastasis (p = 0.009), ALP ≥ 220 U/L (p = 0.001), age ≤ 65 years (p = 0.034), hemoglobin < 9 g/dL (p = 0.006), and early biochemical progressive disease after 1-2 courses (p < 0.001). Newly occurring or worsening hematologic or renal impairments ≥ CTCAE °3 were uncommon. CONCLUSION: In conclusion, the retrospective real-world analysis suggests that individualized, dose-adapted 177Lu based PSMA RLT regimens may provide an opportunity to successfully extend applicability of RLT to more challenging clinical scenarios and a broader patient population without compromising safety and survival outcomes.
引用
- Misirci M, Rosar F, Khreish F, et al. Real-world evaluation of [177Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohort. Eur J Nucl Med Mol Imaging. 2026. PMID: 42412178. doi:10.1007/s00259-026-08037-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。